The 4-aminoquinolines, including
chloroquine and
hydroxychloroquine, have been successfully employed to treat patients with
granuloma-forming disease-associated,
vitamin D metabolite-mediated
hypercalcemia. The
calcium-lowering efficacy of these drugs has not been prospectively evaluated in patients with
lymphoma and elevated 1,25-(OH)2D levels. Four such hypercalcemic patients with stage IV
B-cell lymphoma were treated, two each, with either 400 mg daily oral
hydroxychloroquine or a single course of
prednisone-containing antitumor
chemotherapy (CHOP). Antitumor
therapy normalized the serum
calcium and 1,25-(OH)2D concentration within 5 days. Over a 15-day period,
hydroxychloroquine failed to reduce either the serum
calcium or 1,25-(OH)2D level in
lymphoma patients. In contrast, within 5 days 400 mg of
hydroxychloroquine daily lowered elevated levels of
calcium and 1,25-(OH)2D by 37% and 72%, respectively, in a hypercalcemic patient with
sarcoidosis. These data suggest that regulation of the
vitamin D-1-hydroxylase in
lymphoma cells, the putative source of
hormone in
lymphoma patients, is refractory to the inhibitory actions of the
aminoquinolines and that
glucocorticoid-containing antitumor regimens are the antihypercalcemic
therapies of choice in
lymphoma patients with high 1,25-(OH)2D levels.